Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery.

Area of Science:

• Oncology
• Nanomedicine
• Immunotherapy
• Cellular Therapy

Background:

• Nanotherapy effectively delivers molecules to cancer cells via the enhanced permeability and retention effect.
• Chimeric antigen receptor (CAR)-T cell therapy offers specific cancer cell targeting but struggles with solid tumors due to immunosuppression and resistance.
• Current cancer treatment landscape seeks innovative approaches to overcome therapeutic limitations.

Purpose of the Study:

• To review the targetability and delivery capabilities of nanotherapy and cellular therapy individually.
• To explore the synergistic effects and achievements of combined nano-immunotherapy strategies in cancer treatment.
• To suggest future perspectives for combined nano-immunotherapy approaches.

Main Methods:

• Review of existing literature on nanotherapy and cellular therapy (including CAR-T) in cancer treatment.
• Analysis of targetability and delivery mechanisms for individual and combined therapeutic modalities.
• Discussion of clinical trials and outcomes for nano-immunotherapy strategies.

Main Results:

• Nanotherapy excels in molecular delivery, while CAR-T therapy provides specific targeting.
• Combined nano-immunotherapy strategies demonstrate potential for enhanced efficacy in overcoming solid tumor challenges.
• Ongoing clinical trials are investigating the synergistic benefits of this combination approach.

Conclusions:

• The combination of nanotherapy and immunotherapy, particularly CAR-T, presents a promising strategy to enhance cancer treatment efficacy.
• Addressing limitations in targetability and delivery through combined approaches holds significant potential for overcoming current therapeutic challenges.
• Further research and clinical investigation into nano-immunotherapy are warranted for future cancer treatment perspectives.